Antiviral Drugs - EU-27

EU-27

The Antiviral Drugs market in the EU-27 is estimated to witness a substantial growth in revenue by 2024, with projected earnings reaching US$5.72bn.
Moving forward, the market is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of 1.43%, leading to a market volume of US$6.14bn by 2029.
In terms of global comparison, United States is predicted to generate the highest revenue, amounting to US$30,640.00m in 2024.
Germany, being a leader in pharmaceutical innovation, is experiencing a surge in demand for antiviral drugs due to the increasing prevalence of viral infections.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in EU-27 has been experiencing significant growth in recent years.

Customer preferences: Customers in the EU-27 region have shown a preference for antiviral drugs due to the increasing prevalence of viral infections. The COVID-19 pandemic has further reinforced this trend, with a surge in demand for antiviral drugs that can be used to treat the virus.

Trends in the market: One of the major trends in the Antiviral Drugs market in EU-27 is the development of new antiviral drugs that are more effective and have fewer side effects. This has led to increased competition among pharmaceutical companies, with many investing heavily in research and development to create new and innovative drugs.Another trend in the market is the increasing adoption of antiviral drugs for preventive purposes. As more people become aware of the benefits of antiviral drugs in preventing viral infections, there has been a rise in demand for these drugs.

Local special circumstances: The Antiviral Drugs market in EU-27 is characterized by a highly regulated environment, with strict regulations governing the production and distribution of drugs. This has led to a concentration of market power among a few large pharmaceutical companies that have the resources to comply with these regulations.

Underlying macroeconomic factors: The Antiviral Drugs market in EU-27 is also influenced by macroeconomic factors such as population growth, healthcare spending, and government policies. The aging population in the region has led to an increase in the prevalence of viral infections, driving demand for antiviral drugs. Additionally, government policies aimed at improving access to healthcare have contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.